Results 301 to 310 of about 12,042,484 (342)

Correlation of greyzone fibrosis compared to troponin T and late gadolinium enhancement with survival and ejection fraction in patients after acute myocardial infarction. [PDF]

Clin Res Cardiol
Schmitt R, Staats C, Kaier K, Ahlgrim C, Hein M, Brado J, Steinhoff P, Billig H, Soschynski M, Krauss T, Schlett CL, Westermann D, Neumann FJ, Ruile P, Breitbart P.   +14 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Troponin T Assessment Allows for Identification of Mutation Carriers among Young Relatives of Patients with LMNA-Related Dilated Cardiomyopathy. [PDF]

J Clin Med
Chmielewski P, Kowalik I, Truszkowska G, Michalak E, Ponińska J, Sadowska A, Kalin K, Jaworski K, Minota I, Krzysztoń-Russjan J, Zieliński T, Płoski R, Bilińska ZT.   +12 more
europepmc   +1 more source

Matrix metalloproteinase inhibition protects against junctophilin‐2 proteolysis during doxorubicin‐induced cardiotoxicity

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Treatment of cancer patients with anthracyclines is known to cause dose‐dependent cardiotoxicity through several mechanisms including enhanced oxidative stress, ultimately resulting in defective excitation–contraction coupling.
Wesam Bassiouni, Brandon Y. H. Chan, Andrej Roczkowsky, Joshua W. Kranrod, Zabed Mahmud, Joseph O. Primeau, Woo Jung Cho, Howard S. Young, John M. Seubert, Richard Schulz   +9 more
wiley   +1 more source

Sex-specific high-sensitivity troponin T cut-points have similar safety but lower efficacy than overall cut-points in a multisite U.S. cohort. [PDF]

Acad Emerg Med
Montgomery CM, Ashburn NP, Snavely AC, Allen B, Christenson R, Madsen T, McCord J, Mumma B, Hashemian T, Supples M, Stopyra J, Wilkerson RG, Mahler SA.   +12 more
europepmc   +1 more source

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The increasing number of cancer survivors has caused growing concern over chemotherapy‐induced cardiotoxicity. This study aimed to investigate a novel human model of cardiotoxicity and explore cardioprotection. Experimental Approach Living myocardial slices (LMS) were obtained from explanted end‐stage heart failure ...
Jort S. A. van der Geest, Ilse R. Kelters, Bauke Arends, Willem B. van Ham, Ernest Diez Benavente, Thirza A. Lapré, Petra van der Kraak, Pim van der Harst, Arco J. Teske, Andreas Dendorfer, M. Mostafa Mokhles, Pieter A. Doevendans, Teun P. de Boer, Linda W. van Laake, Joost P. G. Sluijter, Vasco Sampaio‐Pinto   +15 more
wiley   +1 more source

Cardiac troponin T (cTnT) assessment using incompletely filled K2EDTA blood tubes is reliable. [PDF]

Einstein (Sao Paulo)
Lippi G, Salvagno GL.
europepmc   +1 more source

Differences in Troponin I and Troponin T Release in High-Performance Athletes Outside of Competition. [PDF]

Int J Mol Sci
Wuestenfeld JC, Kastner T, Hesse J, Fesseler L, Frohberg F, Rossbach C, Wolfarth B.   +6 more
europepmc   +1 more source

Prognostic Value and Determinants of High-Sensitivity Cardiac Troponin T in Patients With a Systemic Right Ventricle: Insights From the SERVE Trial. [PDF]

J Am Heart Assoc
Ruperti-Repilado FJ, Tran F, Haaf P, Lopez-Ayala P, Greutmann M, Schwerzmann M, Bouchardy J, Gabriel H, Stambach D, Rutz T, Schwitter J, Wustmann K, Freese M, Mueller C, Tobler D.   +14 more
europepmc   +1 more source

Performance of D-dimer, cardiac troponin T, C-reactive protein, and NT-proBNP in prediction of long-term mortality in patients with suspected pulmonary embolism. [PDF]

Eur Heart J Open
Kauppi J, Airaksinen KEJ, Lehto J, Pouru JP, Saha J, Purola P, Jaakkola S, Lehtonen J, Vasankari T, Juonala M, Kiviniemi T.   +10 more
europepmc   +1 more source